Related Experiment Video
Updated: Sep 10, 2025

Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions
Published on: July 2, 2020
Master Protocols: A Promising Approach to Accelerate Drug Development in Rare Kidney Diseases
Julie Lin1, Jai Radhakrishnan2
1Sanofi, Cambridge, MA and Brigham and Women's Hospital, MRB-4, 75 Francis Street, Boston, MA, USA. julierenal@gmail.com.
Drug development for kidney diseases is advancing with new surrogate endpoints. Proteinuria reduction and slowing estimated glomerular filtration rate decline are accelerating clinical trials and investment.
Area of Science:
- Nephrology and drug development.
- Advancements in clinical trial design for kidney diseases.
Background:
- Traditional kidney disease drug development faced hurdles due to lengthy clinical trial endpoints like dialysis or transplantation.
- These lengthy trials required significant time and participant numbers, hindering therapeutic innovation.
Related Concept Videos
Renal Drug Clearance: Overview
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Chronic Kidney Disease III: Interprofessional Care
Kidney Transplant I: Introduction
Renal Drug Excretion: Overview
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Drug Elimination by Renal Route: Tubular Secretion

